PRMT5 and cancer: In MTAP-deleted tumors, increased intracellular concentrations of methylthioadenosine (MTA), the metabolite cleaved by the MTAP enzyme, couple with PRMT5, compete with SAM and, as a result, inhibit PRMT5’s enzymatic activity and contribute to the proposed synthetic lethality in these cancers [49, 50].